XM does not provide services to residents of the United States of America.
G
G

GalpEnergia

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Bunzl, Equinor ASA, L'Oreal

EUROPE RESEARCH ROUNDUP-Bunzl, Equinor ASA, L'Oreal Oct 14 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Bunzl, Equinor ASA and L'Oreal, on Monday. HIGHLIGHTS * Adidas AG ADSGn.DE : UBS raises target price to EUR 279 from EUR 275 * Bunzl BNZL.L : JP Morgan raises to overweight from neutral * Equinor ASA EQNR.OL : Morgan Stanley raises to equal weight from underweight * L'Oreal OREP.PA : Citigroup cuts target price to EUR 420 from
A
A
A
B
B
B
D
D
E
G
G
H
H
I
K
L
L
O
P
S
V
V
W
A
A
B
D
G
I
Y

Galp Q3 Working Interest Production Up 6% Vs Q2

BRIEF-Galp Q3 Working Interest Production Up 6% Vs Q2 Oct 14 (Reuters) - Galp Energia SGPS SA GALP.LS : Q3 SALES OF OIL PRODUCTS TO CLIENTS UP 4% AT 1.9 MILLION TONNES VERSUS 1.8 MILLION TONNES IN Q2 Q3 NATURAL GAS SALES TO CLIENTS UP 3% AT 4.0 TWH VERSUS 3.9 TWH IN Q2 Q3 WORKING INTEREST PRODUCTION UP 6% AT 112,000 BARRELS OF OIL EQUIVALENT PER DA
G

US regulator denies Shell's request for older Venture Global LNG's documents

US regulator denies Shell's request for older Venture Global LNG's documents HOUSTON, Oct 10 (Reuters) - Shell SHEL.L on Thursday lost a bid to have U.S. regulators allow it to view nonpublic commissioning documents related to Venture Global LNG's Calcasieu Pass facility, a setback in a broader dispute over access to cargoes from the plant. Shell, BP BP.L , Galp GALP.LS , Repsol GALP.LS , Orlen PKN.WA and Edison EDNn.MI have launched contract arbitration cases in the U.S.
B
R
G

Exane sees OPEC+ excess capacity looming over oil & gas sector

BUZZ-Exane sees OPEC+ excess capacity looming over oil & gas sector ** Exane BNP Paribas says it sees a "substantial" excess OPEC+ capacity hanging over the oil & gas sector "like the Sword of Damocles", anticipating a new phase for oil markets ** The broker warns that the excess OPEC+ capacity is colliding with insufficient global demand to absorb next year's expected non-OPEC supply growth ** Exane says the Brent oil price will have to move to a $60-65 per barrel level that may not only stimul
B
C
O
R
G

Bureau Veritas, Covestro AG, Redcare Pharmacy NV

EUROPE RESEARCH ROUNDUP-Bureau Veritas, Covestro AG, Redcare Pharmacy NV Oct 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Bureau Veritas, Covestro AG and Redcare Pharmacy NV, on Wednesday. HIGHLIGHTS * British Land BLND.L : Deutsche Bank raises to buy from hold * Bureau Veritas BVI.PA : JP Morgan cuts to neutral from overweight * Covestro AG 1COV.DE : Jefferies cuts to hold from buy * Redcare Pharmacy NV RDC.DE : HSBC raises t
A
A
A
B
B
B
D
E
E
E
E
E
E
E
F
G
I
M
M
A
A
A
A
B
B
E
G
Z

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.